BCL2L1
Bcl-2-like protein 1
As of the edition of 20 October 2026, BCL2L1 (bcl-2-like protein 1, UniProt Q07817) has 7 drugs tested at it and 9 companies on the list, 6 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q07817
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 126
- Disease areas
- Cancer; Blood and lymph; Immune system; Lungs and airways; Hormones; Urinary and reproductive; Pregnancy and women's health; Eye
- Registered trials of its drugs
- 83
Drugs at this target
| Status | Count |
|---|---|
| Active | 2 |
| Stopped | 3 |
| Status not established | 2 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Navitoclax | Active | Phase 3 | none listed |
| Obatoclax | Stopped | Phase 3 | none listed |
| Pelcitoclax | Stopped | Phase 2 | none listed |
| LP-118 | Active | Phase 2 | none listed |
| DT-2216 | Stopped | Phase 2 | none listed |
| UBX1325 | Status not established | Phase 2 | none listed |
| Foselutoclax | Status not established | Phase 2 | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 6 |
| Engaged | 3 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| Ascentage Pharma | Route A |
| Teva | Route A |
| Roche | Route A |
The other 6 companies at BCL2L1
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at BCL2L1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.